Media ReleasesBionomics Limited

View All Bionomics Limited News

Bionomics Limited (ASX:BNO) BNC105 Renal Cancer Trial To Be Presented AT ASCO

Bionomics Limited (ASX: BNO) (ADR: BMICY) will display a poster presentation outlining the BNC105 clinical trial in patients with progressive metastatic renal cancer at the annual American Society for Clinical Oncology (ASCO) meeting in Chicago, Illinois.

Dr Thomas E Hutson of the Baylor Sammons Cancer Center-Texas Oncology is lead author and also Principal Investigator of the trial, which is being conducted for Bionomics by the Hoosier Oncology Group. The presentation will be given during the Trials in Progress Poster Session 8am to 12pm Monday 6 June in McCormick Place Hall A.
On 1 April 2011 Bionomics announced the presentation of preclinical data supporting the current trial in patients with renal cancer at the American Association for Cancer Research (AACR). The data demonstrated the potent vascular disrupting effects of BNC105 in two mouse models of renal cancer, including a model in which the cancer spreads to the lungs.  BNC105 induced tumour blood vessel shutdown in both the primary tumour and the secondary lung cancer.
Sutent, a tyrosine kinase inhibitor (TKI), is used in first line therapy of renal cancer. BNC105 activity was shown to be comparable with the blockbuster drug Sutent which had worldwide sales of US$1.066 billion in 2010.
Treatment options remain limited in progressive metastatic renal cell cancer for patients who no longer respond to TKI treatments such as Sutent. The BNC105 trial is being conducted in patients who have failed TKI therapy and are also being treated with Afinitor, an mTOR inhibitor.
Dr Thomas E Hutson commented "The mechanism of action of BNC105 provides an innovative approach to the treatment of solid tumours including metastatic renal carcinoma, by attacking established tumour vasculature. It is particularly exciting to be conducting a trial which has the potential of creating a new paradigm for the treatment of renal cancer."
"It makes sense that the combination of BNC105 with an agent active against mTOR would cut off a tumour "survival" response and improve clinical outcome. This clinical trial builds on our experience in the treatment of metastatic renal cancer with mTOR inhibitors and our preclinical data," he added.
Renal cell carcinoma accounts for approximately 85 per cent of kidney cancers, with kidney cancer accounting for 2-3 per cent of human malignancies. The incidence of renal cell cancer has been rising steadily. Every year approximately 200,000 cases are diagnosed worldwide, with 55,000 people diagnosed in the US. The five year survival rate for patients with metastatic disease is less than 2 per cent.
Download this document